Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H20O5S |
Molecular Weight | 336.403 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)OC(=O)C(OCC2CC2)=C1C3=CC=C(C=C3)S(C)(=O)=O
InChI
InChIKey=FULAPETWGIGNMT-UHFFFAOYSA-N
InChI=1S/C17H20O5S/c1-17(2)14(12-6-8-13(9-7-12)23(3,19)20)15(16(18)22-17)21-10-11-4-5-11/h6-9,11H,4-5,10H2,1-3H3
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4033 |
0.16 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PREVICOX Approved UseFor the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Launch Date2008 |
|||
Primary | PREVICOX Approved UseFor the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. Launch Date2008 |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. | 2004 Apr |
|
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia. | 2005 Jul |
|
Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. | 2006 Oct 21 |
|
The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors. | 2006 Sep |
|
Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. | 2006 Summer |
|
Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study. | 2006 Summer |
|
[European symposium about osteoarthritis in a dog]. | 2007 Jan 1 |
|
Quantitative HPLC-UV method for the determination of firocoxib from horse and dog plasma. | 2007 Jul 1 |
|
Evaluation of the adverse effects of oral firocoxib in healthy dogs. | 2007 Jun |
|
Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses. | 2007 Jun |
|
Automated liquid chromatography-tandem mass spectrometry method for the analysis of firocoxib in urine and plasma from horse and dog. | 2007 Jun 15 |
|
Firocoxib efficacy preventing urate-induced synovitis, pain, and inflammation in dogs. | 2007 Spring |
|
Switching NSAIDs in practice: insights from the Previcox (firocoxib) Experience Trial. | 2007 Winter |
|
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs. | 2008 Feb |
|
Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. | 2008 Jan 1 |
|
Pharmacokinetics of firocoxib after administration of multiple consecutive daily doses to horses. | 2008 Nov |
|
Effects of firocoxib, meloxicam, and tepoxalin on prostanoid and leukotriene production by duodenal mucosa and other tissues of osteoarthritic dogs. | 2008 Sep |
|
Effect of firocoxib or flunixin meglumine on recovery of ischemic-injured equine jejunum. | 2009 Aug |
|
Confirmatory analysis of firocoxib in bovine milk by rapid resolution liquid chromatography tandem mass spectrometry. | 2009 Feb 15 |
|
Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. | 2009 Jan-Feb |
|
The use of force plate measurements to titrate the dosage of a new COX-2 inhibitor in lame horses. | 2009 Mar |
|
Effect of nonsteroidal anti-inflammatory drugs with varied cyclooxygenase-2 selectivity on cyclooxygenase protein and prostanoid concentrations in pyloric and duodenal mucosa of dogs. | 2009 Oct |
|
The effects of firocoxib (Previcox) in geriatric dogs over a period of 90 days. | 2009 Sep |
|
The effect of doxycycline on canine hip osteoarthritis: design of a 6-months clinical trial. | 2009 Sep |
|
Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies. | 2010 Oct |
|
Effects of firocoxib, meloxicam, and tepoxalin administration on eicosanoid production in target tissues of healthy cats. | 2010 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM218719.pdf http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/DrugLabels/UCM422171.pdf http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/DrugLabels/UCM050387.pdf
The recommended dosage of PREVICOX (firocoxib) for oral administration in dogs is 2.27 mg/lb (5.0 mg/kg) body weight once daily as needed for osteoarthritis and for 3 days as needed for postoperative pain and inflammation associated with soft-tissue and orthopedic surgery. The recommended dosage of EQUIOXX (firocoxib) for oral administration in horses is 0.045 mq/lb (0.1 mg/kg) of body weight once daily for up to 14 days. The recommended dosage of EQUIOXX Injection for intravenous administration in horses is 0.04 mg/lb (0.09 mg/kg) of body weight once daily for up to 5 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26618729
Equine peripheral blood mononuclear cells were isolated by density gradient centrifugation and incubated at 37C with medium alone, firocoxib (100 ng/mL), LPS (1 ng/mL or 1 ug/mL), or combinations of firocoxib and both LPS concentrations. After 4 hours, supernatants were collected and tested for prostaglandin E2 (PGE2) concentration with an enzyme inhibition assay, and gene expression in cell lysates was measured with PCR assays.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
PREVICOX [AUTHORIZED]
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
EQUIOXX (AUTHORISED)
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
||
|
WHO-VATC |
QM01AH90
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
||
|
CFR |
21 CFR 522.930
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
||
|
CFR |
21 CFR 520.930
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
||
|
CFR |
21 CFR 520.928
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m5388
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | Merck Index | ||
|
189954-96-9
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
758895
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
FIROCOXIB
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
C487384
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
OO-25
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL69998
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
Y6V2W4S4WT
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
76136
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
DB09217
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
DTXSID40870188
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
300000023724
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
C65686
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
8359
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
Y6V2W4S4WT
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | |||
|
473298
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY | RxNorm | ||
|
208910
Created by
admin on Fri Dec 15 16:24:15 GMT 2023 , Edited by admin on Fri Dec 15 16:24:15 GMT 2023
|
PRIMARY |
ACTIVE MOIETY